Search Result

Results for "

Opioid-induced

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Arrestin (3) Chloride Channel (1) Endogenous Metabolite (1) ERK (2) iGluR (4) Isotope-Labeled Compounds (3) Neurotensin Receptor (2) Opioid Receptor (10) Sodium Channel (2)
By Research Areas:	Cancer (4) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (16)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19627A

Naldemedine tosylate 1 Publications Verification S-297995 tosylate	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) tosylate is an orally active *μ-opioid* receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (K_i=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀*=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid* receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Metabolic Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting *μ-opioid* receptor antagonist with a target K_i** of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .

HY-14785

Befiradol NLX-112; F13640	5-HT Receptor	Neurological Disease
Befiradol (NLX-112) is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol can be used in studies related to opioid-induced respiratory depression .

HY-171844

CX1739	iGluR	Neurological Disease Inflammation/Immunology
CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .

HY-164795A

SBI-810 hydrochloride	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 hydrochloride is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 hydrochloride promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 hydrochloride inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 hydrochloride effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 hydrochloride is applicable to research related to multiple pain disorders .

HY-164795

SBI-810	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders .

HY-19627

Naldemedine S-297995	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) is an orally active *μ-opioid* receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀*=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid* receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-113254

13,14-Dihydro-15-keto-PGE2	Endogenous Metabolite 5-HT Receptor	Metabolic Disease
13,14-Dihydro-15-keto-PGE2 participates in Bifidobacterium animalis F1-7 to alleviate opioid-induced constipation by 5-HT pathway .

HY-B0680

Lubiprostone (hemiketal) RU-0211 (hemiketal); SPI-0211 (hemiketal)	Chloride Channel	Others Cancer
Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .

HY-144606

*Mu opioid* receptor antagonist 1**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active *μ opioid* receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀** of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease Cancer
Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting *μ-opioid* receptor antagonist with a target K_i** of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .

HY-14785A

Befiradol hydrochloride NLX-112 hydrochloride; F 13640 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Befiradol (NLX-112) hydrochloride is a highly selective 5-HT₁A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol hydrochloride attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol hydrochloride can be used in studies related to opioid-induced respiratory depression .

HY-16765

Axelopran TD-1211	Opioid Receptor	Neurological Disease
Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-A0118AS

Naloxegol-d5 oxalate	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S1

Naloxegol-13C,d2 NKTR-118-¹³C_{,d₂; AZ-13337019-¹³C_,d₂}	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease Cancer
Naloxegol- ¹³C,d₂ (NKTR-118- ¹³C,d₂) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S

Naloxegol-13C,d3 NKTR-118-¹³C_{,d₃; AZ-13337019-¹³C_,d₃}	Isotope-Labeled Compounds	Neurological Disease Cancer
Naloxegol- ¹³C,d₃ (NKTR-118- ¹³C,d₃) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-16765A

Axelopran sulfate TD-1211 sulfate	Opioid Receptor	Neurological Disease
Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-120925

TRV0109101	Opioid Receptor Arrestin	Neurological Disease
TRV0109101 is a *μ-opioid* peptide receptor (MOPR) selective agonist (K_D = 70 nM) with blood-brain barrier permeability. TRV0109101 selectively promotes G protein signaling pathway coupling while reducing the recruitment of β-arrestin*. TRV0109101 inhibits opioid-induced* mechanical hyperalgesia and induces antinociceptive tolerance. TRV0109101 is applicable for pain-related research .

HY-182631

CX1763	iGluR	Neurological Disease
CX1763 is an AMPAR allosteric modulator. CX1763 allosterically potentiates glutamate-evoked currents, accelerates channel opening, and increases the surface levels of AMPAR containing Glur2 (R). CX1763 enhances synaptic transmission in the rat hippocampus. CX1763 improves attention in rats and attenuates amphetamine-induced hyperactivity in mice. CX1763 can be used in studies related to attention deficit hyperactivity disorder and opioid-induced respiratory depression .

Cat. No.	Product Name	Chemical Structure

HY-A0118AS

Naloxegol-d5 oxalate
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S1

Naloxegol-13C,d2
Naloxegol- ¹³C,d₂ (NKTR-118- ¹³C,d₂) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S

Naloxegol-13C,d3
Naloxegol- ¹³C,d₃ (NKTR-118- ¹³C,d₃) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.